MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Aandelen Lijst・Gossamer Bio Inc

Gossamer Bio Inc

Gesloten

SectorGezondheidszorg

0.37 5.71

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.36

Max

0.38

Belangrijke statistieken
By Trading Economics
Inkomsten	983K -47M
Verkoop	505K 14M
Winstmarge	-342.329
Werknemers	161
EBITDA	-346K -46M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+1089.19% upside

Dividenden
By Dow Jones
Volgende Winsten	14 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-30M 75M
Vorige openingsprijs	-5.34
Vorige sluitingsprijs	0.37

Nieuwssentiment

By Acuity

97%

331 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

1.06 / 1.23 Steun & Weerstand

Gossamer Bio Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 apr 2026, 04:27 UTC

Belangrijke Nieuwsgebeurtenissen

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3 apr 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 18:30 UTC

Belangrijke Nieuwsgebeurtenissen

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 apr 2026, 18:14 UTC

Marktinformatie

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 apr 2026, 17:50 UTC

Marktinformatie

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 apr 2026, 17:44 UTC

Acquisities, Fusies, Overnames

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 apr 2026, 16:50 UTC

Belangrijke Nieuwsgebeurtenissen

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 apr 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 16:12 UTC

Winsten

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 apr 2026, 15:56 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 apr 2026, 15:56 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

3 apr 2026, 15:56 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2026, 15:20 UTC

Belangrijke Nieuwsgebeurtenissen

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 apr 2026, 15:08 UTC

Acquisities, Fusies, Overnames

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 apr 2026, 14:11 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 apr 2026, 12:56 UTC

Marktinformatie

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 apr 2026, 08:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 08:01 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 apr 2026, 08:01 UTC

Marktinformatie

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 apr 2026, 07:45 UTC

Marktinformatie

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Marktinformatie

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 apr 2026, 04:33 UTC

Marktinformatie

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 apr 2026, 04:33 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 apr 2026, 04:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

3 apr 2026, 04:01 UTC

Marktinformatie

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3 apr 2026, 02:01 UTC

Marktinformatie

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3 apr 2026, 01:59 UTC

Marktinformatie

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3 apr 2026, 01:44 UTC

Marktinformatie

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3 apr 2026, 01:22 UTC

Marktinformatie

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Peer Vergelijking

Prijswijziging

Gossamer Bio Inc Prognose

Koersdoel

By TipRanks

1089.19% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.4 USD 1089.19%

Hoogste 15 USD

Laagste 0.3 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Gossamer Bio Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Gossamer Bio Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.06 / 1.23Steun & Weerstand

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

331 / 349 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.